Takeda Pharmaceuticals, Japan's largest drugmaker, has undergone a sweeping transformation under CEO Christophe Weber, ...

The pharmaceutical industry's next billion-dollar blockbuster won't come from a lab alone—it will come from listening to ...

The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.

Long a lobbying powerhouse in Washington, pharma’s struggling to settle on a strategy for defending itself, according to six industry lobbyists and three company officials who spoke to POLITICO. All ...

Roche has pledged to build a giant weight-loss drug factory in the US. The plans form part of a $50bn (£37bn) pledge aimed at ...

We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going ...

Europe’s largest pharmaceutical companies are calling on the EU leadership to significantly increase the purchase and sales prices of ...

Pfizer, Novartis, Amgen, Eli Lilly and J&J lead pharma lobbying spend amid policy changes. Issues include 340B program, drug ...

One of the company’s subsidiaries, Lupin Diagnostics Limited, has become the first 100 per cent NABL accredited company in ...

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of ...

The biopharmaceutical industry saw a strong start to 2025, despite ongoing uncertainty around the potential impact of US ...